Foster Victor Wealth Advisors LLC Grows Position in Pfizer Inc. (NYSE:PFE)

Foster Victor Wealth Advisors LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 6.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 598,475 shares of the biopharmaceutical company's stock after acquiring an additional 34,440 shares during the quarter. Pfizer comprises about 1.2% of Foster Victor Wealth Advisors LLC's portfolio, making the stock its 27th largest holding. Foster Victor Wealth Advisors LLC's holdings in Pfizer were worth $15,165,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of PFE. Lipe & Dalton raised its position in Pfizer by 17.7% in the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 400 shares during the last quarter. Beam Wealth Advisors Inc. increased its stake in Pfizer by 1.5% in the fourth quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company's stock valued at $728,000 after purchasing an additional 401 shares during the period. Providence Capital Advisors LLC raised its holdings in shares of Pfizer by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock valued at $3,034,000 after buying an additional 409 shares during the last quarter. Donaldson Capital Management LLC boosted its stake in shares of Pfizer by 1.2% during the fourth quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company's stock worth $947,000 after buying an additional 410 shares during the period. Finally, Noesis Capital Mangement Corp grew its holdings in shares of Pfizer by 2.6% during the fourth quarter. Noesis Capital Mangement Corp now owns 16,357 shares of the biopharmaceutical company's stock worth $434,000 after buying an additional 413 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of PFE traded down $0.13 during trading hours on Wednesday, reaching $23.88. The company had a trading volume of 36,273,498 shares, compared to its average volume of 41,200,698. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The firm has a 50 day simple moving average of $23.14 and a 200-day simple moving average of $24.93. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a market capitalization of $135.74 billion, a price-to-earnings ratio of 17.30, a PEG ratio of 0.89 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. Pfizer's revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.82 earnings per share. Research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.20%. Pfizer's dividend payout ratio is presently 124.64%.

Wall Street Analysts Forecast Growth

Several analysts have commented on PFE shares. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. UBS Group upped their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. Finally, The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.